B acute lymphoblastic leukemia (B-ALL) is a fatal blood cell tumor that is usually treated with chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HCT), and CD19-CAR-T cell therapy has been successful in treating refractory or relapsed (r/r) B-ALL patients. However, some patients would become refractory to all these treatment options and relapse. In this study, we evaluated humanized CD22-CAR-T cell therapy as a treatment option for pediatric r/r B-ALL patients who failed multiple lines of treatment including allo-HCT and CD19-CAR-T cell therapy. Shanghai Yake Biotech company provided the lentiviral vector with a humanized anti-CD22 CAR design. We produced the CD22-CAR-T cells and conducted the clinical protocols in our hospital. The treatment is highly effective with an overall response rate (ORR) of 86.7% and complete remission (CR) rate of 80.0%. The response cases achieved progression-free survival (PFS) rate of 91.7% during a median follow-up of 108 (46-199) days. It also has excellent safety profile with minor side effects and no death. Our study shows that CD22-CAR-T cell therapy is a highly effective and safe treatment option for pediatric r/r B-ALL patients even after they failed CD19-CAR-T therapy and allo-HCT. It gives these otherwise untreatable patients a new hope.
Presenter: Dr Jing Pan
Affiliation: Beijing Boren Hospital, Beijing, China
Topic: EFFICACY AND SAFETY OF CD22-DIRECTED CAR-T CELL THERAPY IN 15 PEDIATRIC REFRACTORY OR RELAPSED B ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS.
Abstract S832 will be presented by Jing Pan on Saturday, June 16, 11:30-11:45 in Room A8.
About the EHA Annual Congress
Every year in June, EHA organizes its Annual Congress in a major European city. After five years, the congress returns to Stockholm. The Congress is aimed at health professionals working in or interested in the field of hematology.
The scientific program topics range from stem cell physiology and development, to leukemia; lymphoma; diagnosis and treatment; red blood cells; white blood cells and platelet disorders; hemophilia and myeloma; thrombosis and bleeding disorders as well as transfusion and stem cell transplantation.
Please note that our embargo policy applies to all selected abstracts in the Press Briefings. For more information check our Congress Media Guidelines here.
SOURCE European Hematology Association
Read on The Source